ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

EXEL: Exelixis Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

EXELIXIS INC (NASD)
EXEL	6.71	0.08	(1.21%)	Vol. 1,137,820	16:00 ET

Exelixis Inc. is a leader in the fields of model system genetics andcomparative genomics. These fields involve the systematic study of simpleorganisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.

General Information

EXELIXIS INC

170 Harbor Way P.O. Box 511 South San Francisco, CA 94083 Phone: 650 837-7000 Fax: 650 837-8300 Web: www.exelixis.com Email: cbutler@exelixis.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/10/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	6.63
52 Week High	8.00
52 Week Low	2.42
Beta	1.57
20 Day Moving Average	1,343,618.63
Target Price Consensus	6.25

% Price Change
4 Week	14.90
12 Week	17.51
YTD	33.67

% Price Change Relative to S&P 500
4 Week	13.66
12 Week	10.79
YTD	10.62

Share Information
Shares Outstanding (millions)	107.34
Market Capitalization (millions)	720.23
Short Ratio	8.74
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.25
Current Year EPS Consensus Estimate	-1.23
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/10/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.50
30 Days Ago	2.00
60 Days Ago	2.00
90 Days Ago	2.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	43.59%
vs. Previous Quarter	33.33%

Sales Growth
vs. Previous Year	83.67%
vs. Previous Quarter:	100.63%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	5.25

ROE
09/30/09	-
06/30/09	-
03/31/09	-

ROA
09/30/09	-35.57
06/30/09	-45.31
03/31/09	-48.94

Current Ratio
09/30/09	1.43
06/30/09	1.16
03/31/09	1.30

Quick Ratio
09/30/09	1.43
06/30/09	1.16
03/31/09	1.30

Operating Margin
09/30/09	-97.91
06/30/09	-135.75
03/31/09	-141.02

Net Margin
09/30/09	-105.97
06/30/09	-149.77
03/31/09	-146.45

Pre-Tax Margin
09/30/09	-105.97
06/30/09	-149.77
03/31/09	-146.45

Book Value
09/30/09	-1.33
06/30/09	-1.16
03/31/09	-0.84

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-0.47
06/30/09	-0.56
03/31/09	-0.81

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research